Page 8 - Sci Communications News Today

Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference USA - English Share this article Share this article HOLON, Israel, March 8, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Oppenheimer 31 st Annual Healthcare Conference (virtual), on Tuesday, March 16, 2021 at 10:40 AM ET. A live webcast of the presentation w...

DUBLIN, Ireland, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on developing FT218, an investigational, ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin Athenex, Inc.February 18, 2021 GMT Athenex Announces Licensing of Additional Territories for the Development and Commercialization of Tirbanibulin in Japan and South Korea. PharmaEssentia Expands Tirbanibulin Partnership by Adding Japan and South Korea to Already Licensed Territories of Taiwan, Singapor...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy ... Athenex, Inc.February 11, 2021 GMT The New England Journal of Medicine published the Phase III trial results on Klisyri®, an anti-proliferative agent that inhibits tubulin polymerization and Src kinase signaling, for the topical treatment of actinic keratosis (AK) of the face or scalp Klisyri®, develo...

RALEIGH, NC / ACCESSWIRE / February 10, 2021 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that its Chief Executive Officer

Oncocyte Announces Pricing of $35 Million Public Offering of Common Stock IRVINE, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) — Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it has priced the previously announced underwritten public offering of 7,780,000 shares of its common stock, at a public offering price of $4.50 per share. The gross pro...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Ziopharm Oncology Announces Election of Robert Postma to its Board of Directors ZIOPHARM Oncology IncFebruary 5, 2021 GMT BOSTON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”), effective immediately. Mr. Postma is the Founder of WaterMill Asset Manag...

9 Meters Biopharma, Inc. highlighted at upcoming Truist Securities CEO Strategic Vision Conference Call Series RALEIGH, NC / ACCESSWIRE / February 3, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced its Executive Management team will participate in the "CEO Strategic Vision" Conference Call Series hosted by hosted by Srikripa Devarakonda, PhD and Robyn Karnauskas, PhD of Truist Securities on Wednesday, Februa...

Our NanoNews Digest Sponsors Home > Press > Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia Abstract: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-finding clinical study of ARO-ANG3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patient...

Oncocyte Announces $25 Million Registered Offering Offering Led by Current Shareholder and Healthcare Investor, Pura Vida Investments, Substantially Increasing Its Holdings Further Strengthens Balance Sheet to Support Ongoing Commercial and Development Activities across Cancer Care Continuum IRVINE, Calif., Jan. 20, 2021 — Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care c...